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A human enzyme variant, PON1-G3C9, accidentally catalyzes the hydrolysis of organophosphorus chemical
weapons. In this issue of Chemistry & Biology, Goldsmith and coworkers describe a new PON1 variant with
improved hydrolysis by several hundred fold; enough that it may protect animals from a toxic dose.Insects have evolved resistance to
organophosphorus insecticides through
evolution, which involved the death of
countless insects (e.g., Newcomb et al.,
1997). Organophosphorus insecticides
inactivate acetyl cholinesterase (AcChE),
a key enzyme in nerve function. Nerve
agents (Figure 1) are similar organophos-
phorus compounds that are highly toxic
to humans and have been manufactured
as chemical weapons. In 1995, a terrorist
group killed thirteen people and injured
fifty by releasing the nerve agent sarin
(or GB) in the Tokyo subway. Although in
principle humans could evolve resistance
to these nerve agents, the entire process
would lead to countless deaths and is
absolutely unacceptable in myriad ways.
Therefore, there is a need for alternative
strategies to address this issue, and one
of the acceptable alternatives is the
laboratory evolution of a human enzymeO
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Figure 1. Structures of several G-series
organophosphorus toxins as well as the structure
of VX
The toxins are racemic mixtures, but the enantiomer shown is
the more toxic one (SP; tabun is an exception due to a different
priority of the substituents). The ideal detoxifying enzyme
should be stable, favor hydrolysis of this more toxic enan-
tiomer and accept all of these substrates. The numbering
ranks the substituents to assign the configuration of the phos-
phorus stereocenter.that can detoxify these compounds.
The work of Goldsmith et al.
(2012),discussed in this issue of
Chemistry & Biology, is an important
step toward this goal.
G. Schrader at IG Farben discov-
ered the first series (now called
the G-series; Figure 1) of organ-
ophosphorus chemical warfare
agents during insecticide research
starting in 1936. Toxins in this series
are volatile and react quickly with
water because the phosphorus con-
tains a good leaving group (usually
fluoride). Because they hydrolyze
in the environment, they are non
persistent. R. Ghosh at Imperial
Chemical Industries in England
discovered the second series
(V-series) starting in 1954, also while
researching insecticides. These
compounds are more toxic, but
also less volatile, making skincontact the primary hazard. The
substituted aminoethanethiol leaving
group makes them less reactive with
water and therefore they persist in the
environment.
The organophosphorus toxins react
quickly with the active site serine of
AcChE to form a covalent link, but the
cleavage of this adduct is slow leading
to an inactivated enzyme. The tetrahedral
geometry of the phosphonyl serine
adduct (as compared to the trigonal
geometry of the acetyl enzyme interme-
diate) sterically hinders the attack of water
and orients the leaving group in a non-
optimal orientation.
Two current defenses against nerve
agents use a stoichiometric approach
using chemicals. Noncovalent AcChE
inhibitors (e.g., pyridostigmine bromide)
block the access of nerve agents to
the active site. Strong nucleophiles, likeChemistry & Biology 19, April 20, 2012oximes, react with phosphonyl-AcChE
complex to cleave the phosphonyl group
and reactivate the enzyme. These
approaches still involve inhibition of the
AcChE, which causes serious side effects
(review Doctor and Saxena, 2005).
A third approach uses a sacrificial
enzyme, human butyryl cholinesterase
(HuBChE), to react with the nerve agent
instead of AcChE. By combining this
approach with a strong nucleophile, the
HuBChE can inactivate more than one
molecule of nerve agent, but this
approach still requires a large, 200 mg,
dose of protein (Lenza et al., 2007).
Insect resistance to organophosphorus
insecticides uses a catalytic approach
where one enzyme detoxifies many toxin
molecules (Marino, 2007). A similar
approach may be possible for providing
humans with protection strategy. Several
phosphotriesterases, also known asª201organophosphorus acid anhydride
hydrolases, have been reported in-
cluding a two-zinc metalloenzyme
(PTE, likely a lactonase) from a soil
bacterium, a two-manganesemetal-
loenzyme (likely a proline peptidase)
from a halophilic pond bacterium,
and two two-calcium metalloen-
zymes, PON1, found in liver and
blood (likely a lactonase) from
human serum, and diisopropyl-fluo-
rophosphatase from squid. In each
case, the biological role of the en-
zyme is something else, and the
organophosphorus activity is a pro-
miscuous or accidental ability.
The organophosphorus toxins are
racemicmixtures where the enantio-
mers differ in configuration at phos-
phorus. The enantiomer with the SP
configuration is more toxic, so this
enantiomer is the target for any
detoxification, but enantioselectivity2 Elsevier Ltd All rights reserved 435
Figure 2. Active site structure of calcium-dependent
phosphotriesterase PON1-G2E6, which is similar to
starting variant PON1-G3C9, showing the locations of
the amino acid substitutions
The final variant after four rounds of directed evolution contains
eight amino acid substitutions. Two of these substitutions
(labeled both) are identical to the substitutions found previ-
ously. Three of the substitutions are in new locations (labeled
new; one location (Leu55) cannot be seen in this view). Three
of the substitutions are different substitutions in at previously
mutated locations (labeled changed). Catalysis occurs at the
calcium ion shown in green, which also contains a bound
phosphate anion (sticks representation). Two amino acid resi-
dues (Lys70, Tyr71) in a flexible loop are shown in sticks repre-
sentation to allow a better view of the active site.
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less toxic enantiomer also needs to
be degraded. Unfortunately, the
four organophosphorus hydrolases
all favor hydrolysis of the less toxic
RP enantiomers (e.g., Harvey et al.,
2005). Tsai et al. (2010) previously
reversed the enantioselectivity of
PTE toward the G-series nerve
agents and nerve agent analogs by
rational engineering of the active
site. The enantioselectivity changed
80,000-fold from 760-fold in favor
of the less toxic enantiomer to 110-
fold in favor of the more toxic
enantiomer. The reaction rate for
sarin (GB) with the engineered
enzyme was fast (kcat/KM = 1.4 3
104 M1s1). Two limitations of
PTE as a drug are poor stability
and that it is a bacterial protein,
which will likely cause an immune
response if injected into the blood-
stream. Melzer et al. (2009) also
engineered the squid enzyme to re-
verse the enantioselectivity to favor
the more toxic enantiomer andachieved an impressive rate of kcat/KM =
2.3 3 105 M1s1 for sarin (GB) and
4.9 3 105 M1s1 for cyclosarin (GF).
These values correspond to a 5.5- and
29-fold increase over wild-type.
To minimize the problem of immune
response, Goldsmith et al. (2012) focused
on the human enzyme PON1. This
enzyme is also unstable, but recombina-
tion of homologous enzymes from rabbit,
human, mouse, and rat yielded variant re-
PON1-G3C9, which is more stable and
more easily expressed in Escherichia coli
(Aharoni et al., 2004). This variant is
closest to rabbit enzyme (95% amino
acid sequence identity) and is 86% iden-
tical with the human enzyme. Presumably,
this close relationship to the human
enzyme will minimize any immune
response, but this hypothesis has not
been tested. The two limitations of
the enzyme are slow rate [kcat/KM = 2 3
103 M1s1 toward (SP)-cyclosarin (GF);
the units here are in M1s1 for easy
comparison to other work; the paper lists
values in M1min1] and preference for
the less toxic enantiomer.
In an earlier work, Gupta et al. (2011)
used directed evolution to increase
the rate of hydrolysis 135-fold toward
the more toxic enantiomer (SP)-cyclosarin
reaching an impressive value of436 Chemistry & Biology 19, April 20, 2012 ªkcat/KM = 3 3 10
5 M1s1. The directed
evolution involved screening toward
a less toxic and more easily monitored
analog (a coumaryl leaving group in place
of fluoride). The reaction rate toward the
SP enantiomer of this analog increased
by an impressive factor of 105, but this
increase toward the true substrate, cyclo-
sarin, was a more modest 135-fold. This
improved variant could protect mice
from a lethal dose of the coumaryl analog,
but the protection against cyclosarin was
not tested. The evolved variant 2D8 has
five amino acid substitutions all in the
substrate-binding site.
Now, Goldsmith et al. (2012) use
directed evolution to expand the substrate
range to three otherG-series organophos-
phorus toxins and even includes the slow,
but detectable, hydrolysis of VX from the
less reactive V series of nerve agents.
The researchers first tested the variants
identified previously (Tsai et al., 2010)
and found that they already had a broader
substrate range. The current work im-
proved the rates further by 3- to 340-
fold. These improvements also reversed
the enantioselectivity to an analog of
cyclosarin such that hydrolysis of the toxic
enantiomer is now favored.
Using the X-ray crystal structure (Harel
et al., 2004), the researchers targeted2012 Elsevier Ltd All rights reservedeight positions in the active site for
mutagenesis. Complete randomiza-
tion would create approximately 208
or 26 billion variants, which is far
more than is possible to screen.
The researchers used four different
strategies to limit the number of vari-
ations, but still screened only a small
fraction of possible mutants. For
example, in round 1, only some
amino acid substitutions were allow
at the eight positions so that only
22,000 variations were possible.
Of these, they screened only 2,000,
so better variants may still be found.
The final mutant (Figure 2) cata-
lyzes hydrolysis of soman (GD) and
cyclosarin (GF) at kcat/KM = 7 3
105 M1s1, which the researchers
predict to be fast enough to detoxify
them in animals. Hydrolysis of tabun
(GA) and sarin (GB) are about an
order of magnitude slower, but
they are less toxic so this slower
rate may be enough for detoxifica-
tion. The variant also catalyzes
the hydrolysis of VX kcat/KM =2–4 M1s1, which is very slow, but may
be a good starting point for further
evolution.
The key features of this work are the use
of a mostly human enzyme and the large,
several hundred-fold increases in the
achieved rate. Still left to do is to show
that this enzyme can protect animals
against nerve agents. The researchers
showed that enzyme retains >75%
activity in a blood sample for 24 h, but
immune response and stability to prote-
ases must still be tested. If successful,
the availability of potent detoxifying
agents would render this class of chemi-
cal weapons less effective.REFERENCES
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The deubiquitinating enzymeUSP7 is an emerging oncology and antiviral target. Reverdy et al., in this issue of
Chemistry & Biology, disclose the first small-molecule inhibitor selective for USP7, which recapitulates its
knockdown in cancer cells and hence demonstrates the therapeutic feasibility of USP7 inhibitors.Covalent modification of cellular proteins
by ubiquitin (Ub) represents a highly
versatile posttranslational mechanism
that underpins proteasomal degradation
and regulates a diverse array of cellular
processes (Komander et al., 2009;
Reyes-Turcu et al., 2009). Defects in ubiq-
uitin-based control mechanisms have
been implicated in the pathogenesis of
numerous disease states including
cancer, chronic diseases, and viral infec-
tions (Lindner, 2007; Singhal et al.,
2008). Hence, components of the ubiqui-
tin system emerge as attractive drug
targets, reinforced by the approval of
the proteasome inhibitor Velcade in
oncology. Protein ubiquitination is a
dynamic and reversible process con-
trolled by the coordinated action of
multiple ubiquitin-conjugating and deubi-
quitinating enzymes (DUBs). The human
genome contains nearly 100 DUBs, which
can be divided in five structural classes.
USP7, which is the enzyme targeted for
inhibitor discovery by Colland and co-
workers (Reverdy et al., 2012), is part of
the ubiquitin-specific proteases (USP)
class, a group of cysteine proteases
comprising approximately 60 members.
Several studies have linked USP7 to
diseases, particularly cancer, and the
enzyme is considered a very promisingtarget for drug discovery (Nicholson and
Suresh Kumar, 2011).
A major hurdle in the discovery of
inhibitors for cysteine proteases having
the papain-like fold is achieving inhibi-
tory selectivity. This is due to relatively
shallow substrate-binding sites lined
with residues well conserved over large
families of homologous enzymes. More-
over, high-throughput screening (HTS)
hits have acceptable inhibitory potency
but often do not display the desired level
of selectivity, requiring further optimiza-
tion. Nonetheless, HTS campaigns have
led to several active site-directed small-
molecule USP inhibitors. A cyano-indeno-
pyrazine derivative (HBX 41,108) was
disclosed as a reversible uncompetitive
low mM inhibitor of human USP7 of
modest selectivity against several DUBs
and other cysteine proteases (Colland
et al., 2009; Reverdy et al., 2012). Another
compound was found to inhibit the
proteaseome-activated form of human
USP14 in mM range but to inhibit IsoT
(human USP5) only 20-fold weaker (Lee
et al., 2010). Several structurally unrelated
inhibitors of human USP1 were discov-
ered in mM range but inhibited at least
one other human USP with similar poten-
cies (Chen et al., 2011). Other recent
efforts in the field have lead to com-pounds with often limited assessment
of selectivity. Perhaps the most success-
ful selective inhibition of a USP was
achieved for the PLpro of the SARS coro-
navirus. Small-molecule, non-covalent,
substrate-binding-site-directed inhibitors
of this viral USP were discovered in the
mM range potency and with excellent
selectivity profile (Ratia et al., 2008). This
high selectivity was likely afforded by the
relative divergence of the viral USP from
human USPs both structurally and func-
tionally. In all these cases, the inhibitors
were tested against a very limited set of
USPs or DUBs.
In this issue of Chemistry & Biology,
Reverdy et al. (2012) report 9-chloro
derivatives of amidotetrahydroacridine
as USP7 inhibitors in the mM range,
identified from an in vitro enzymatic
HTS. Importantly, these compounds
show good selectivity for USP7 when
tested against other human USPs and
DUBs. An interesting and commendable
aspect is the use of an activity-based
molecular probe (HAUbVS) that can label
active cellular USPs, giving access to
a large repertoire of USPs therefore
permitting a thorough evaluation of
inhibitory selectivity. The selectivity data
obtained in vitro on cell lysates using
HAUbVS indicate that the inhibitor (HBXª2012 Elsevier Ltd All rights reserved 437
